FDA OKs Merck's Keytruda for triple-negative breast cancer

• The FDA approves Merck's (NYSE:MRK) Keytruda (pembrolizumab), combined with chemo, for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.
• The indication is the 26th in the U.S. for the PD-1 inhibitor.
• https://seekingalpha.com/news/3636313-fda-oks-mercks-keytruda-for-triple-negative-breast-cancer